RePORT ⟩ RePORTER

Skip Navigation Links

Search Results

Project Details

A Prospective Natural History Study of US Patients with a History of Zika Virus Infection

Project Number272201300015I-0-27200008-1

Contact PI/Project LeaderEL SAHLY, HANA

Awardee OrganizationBAYLOR COLLEGE OF MEDICINE

Description

Abstract Text

The Vaccine and Treatment Evaluation Units (VTEUs) are a consortium of individual contracts within academic centers and organizations that provide a ready resource for the design and conduct of clinical trials to evaluate promising vaccines and treatments for infectious disease. Investigations of novel product delivery systems and routes of delivery may also be conducted. In general, products will be evaluated in normal healthy populations; however, access to special populations is also available.

Public Health Relevance Statement

Data not available.

NIH Spending Category

Biodefense Biotechnology Clinical Research Clinical Trials and Supportive Activities Emerging Infectious Diseases Immunization Infectious Diseases Orphan Drug Prevention Rare Diseases Vaccine Related

Project Terms

Conduct Clinical TrialsContractsDiagnosticEmerging Communicable DiseasesEvaluationIndividualInvestigationNatural HistoryPatientsPopulationRecording of previous eventsResourcesRouteSystemVaccine ResearchVaccinesVirus DiseasesZika Virusdesigninfectious disease treatmentnamed groupnovelprospectivetherapeutic vaccine

Details

Contact PI/ Project Leader

Name

EL SAHLY, HANA

Title

Contact

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

BAYLOR COLLEGE OF MEDICINE

City

HOUSTON

Country

UNITED STATES (US)

Department Type

Unavailable

Organization Type

Domestic Higher Education

State Code

Congressional District

Other Information

Opportunity Number

Study Section

Fiscal Year

2016

Award Notice Date

Administering Institutes or Centers

National Institute of Allergy and Infectious Diseases

CFDA Code

DUNS Number

051113330

UEI

FXKMA43NTV21

Project Start Date

13-April-2016

Project End Date

11-January-2020

Budget Start Date

Budget End Date

Project Funding Information for 2016

Total Funding

$1,180,154

Direct Costs

Indirect Costs

Year	Funding IC	FY Total Cost by IC
2016	National Institute of Allergy and Infectious Diseases	$1,180,154

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$1,180,154	Biotechnology; Clinical Research; Clinical Trials and Supportive Activities; Emerging Infectious Diseases; Immunization; Infectious Diseases; Orphan Drug; Rare Diseases; Vaccine Related
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$826,108	Prevention

Sub Projects

No Sub Projects information available for 272201300015I-0-27200008-1

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 272201300015I-0-27200008-1

Patents

No Patents information available for 272201300015I-0-27200008-1

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 272201300015I-0-27200008-1

Clinical Studies

No Clinical Studies information available for 272201300015I-0-27200008-1

News and More

Section Menu